Tanju Serhan, Erus Suat, Selçukbiricik Fatih, İliaz Sinem, Kapdağlı Murat, Bulutay Pınar, Sevinç Tolga Evrim, Mandel Nil Molinas, Dilege Şükrü
1 Department of General Thoracic Surgery, Koç University School of Medicine, Istanbul, Turkey.
2 Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey.
Tumori. 2019 Apr;105(2):155-160. doi: 10.1177/0300891618792463. Epub 2018 Aug 30.
To analyze the extent of visceral pleural invasion (VPI) and its effect on survival along with its place in determining the T descriptor in TNM staging in our patients.
A total of 233 patients underwent lung resection. The data were retrospectively analyzed in terms of sex, age, histopathologic type, stage of the tumor, extent of VPI, and survival. Patients who had neoadjuvant chemotherapy or chemoradiotherapy, distant metastasis, parietal pleural invasion, and operative mortality were excluded.
The median follow-up was 59 months (range 4-126). The extent of VPI was PL0 in 119 (65.7%) patients, PL1 in 47 (26%) patients, and PL2 in 15 (8%) patients. The median survival rates were 65 (range 43-96) months for PL0, 54 (range 37-72) months for PL1, and 39 (range 12-69) months for PL2. The 5-year overall survival rates were 74.7% for PL0, 77.8% for PL1, and 53.3% for PL2. There were statistically significant differences in overall survival among PL0, PL1, and PL2 ( p = 0.03). In subgroup analysis, the difference was insignificant in PL0 vs PL1 ( p = 0.81), but significant in PL0 vs PL2 ( p = 0.02) and PL1 vs PL2 ( p = 0.04) groups.
This study emphasizes that the presence of VPI is related with poor prognosis independent of lymph node positivity, histologic subtypes, and tumor size. As the study shows, PL0 and PL1 have similar survival rates and these two groups may be considered as VPI (-) patients whereas PL2 disease affects survival outcomes.
分析我们的患者中脏层胸膜侵犯(VPI)的程度及其对生存的影响,以及其在TNM分期中确定T描述符方面的作用。
共有233例患者接受了肺切除术。回顾性分析了患者的性别、年龄、组织病理学类型、肿瘤分期、VPI程度和生存情况。排除接受新辅助化疗或放化疗、远处转移、壁层胸膜侵犯和手术死亡的患者。
中位随访时间为59个月(范围4 - 126个月)。119例(65.7%)患者的VPI程度为PL0,47例(26%)患者为PL1,15例(8%)患者为PL2。PL0患者的中位生存率为65个月(范围43 - 96个月),PL1为54个月(范围37 - 72个月),PL2为39个月(范围12 - 69个月)。PL0、PL1和PL2的5年总生存率分别为74.7%、77.8%和53.3%。PL0、PL1和PL2之间的总生存存在统计学显著差异(p = 0.03)。在亚组分析中,PL0与PL1之间差异不显著(p = 0.81),但PL0与PL2之间(p = 0.02)以及PL1与PL2之间(p = 0.04)差异显著。
本研究强调VPI的存在与不良预后相关,与淋巴结阳性、组织学亚型和肿瘤大小无关。如研究所示,PL0和PL1的生存率相似,这两组可被视为VPI(-)患者,而PL2疾病会影响生存结果。